source
- Summit Therapeutics shares tumble 20% after interim Phase 3 miss for ivonescimabSummit Therapeutics saw its shares fall about 20% after the market close on Thursday. The decline came after an interim analysis of a Phase 3 trial for its cancer candidate ivonescimab failed to m…
- Moderna discusses post-marketing data with FDA to expand Covid-19 vaccine labelModerna announced it is working with US regulators to supply post-marketing data on its Covid-19 vaccines. The effort aims to address the FDA's decision last year to narrow the vaccine label, limi…